Key Highlights

  • Myriad Genetics (NASDAQ:MYGN) closed at USD 3.18 on September 8, 2026 and USD 4.575 on October 5, and a published screen shows a one-month gain of 30.03% at USD 4.13 on October 8.
  • The stock rose 10.8% to USD 3.79 on September 14 and 2.4% more to USD 3.88 on September 15 on 4.7 million shares, but the company issued no Earnings or guidance news in that window.
  • Craig-Hallum raised its target to USD 8 from USD 4 with a Buy rating around October 2, 2026, according to a published analyst note, after a double downgrade in early September.
  • Myriad Genetics (NASDAQ:MYGN) reaffirmed 2026 guidance on September 16 while its chief commercial officer, Brian Donnelly, departed on September 21, and Vishal Sikri became executive vice president, commercial.

Rebound After a Downgrade Slump

Myriad was downgraded to Underweight from Overweight at Piper Sandler with a USD 2 target in early September 2026, and UBS assumed coverage with a Neutral rating and a USD 3.60 target around September 9. Stephens had earlier cut its target to USD 3 from USD 5, around August 24. A Barron's headline called it a rare double downgrade tied to profitability concerns. The shares then bounced, rising from USD 3.18 on September 8 to USD 3.88 on September 15. Management presented at the Wells Fargo Healthcare Conference on September 10 at 11:00 a.m. EST, but no new financial information was released. Volume reached 3.9 million shares on September 10 and 4.7 million on September 15, well above recent levels.

Management Changes

On September 16, 2026 Myriad appointed Vishal Sikri, previously senior vice president of product, as executive vice president, commercial, succeeding chief commercial officer Brian Donnelly, who left on September 21. The company reaffirmed its 2026 guidance from the July 30 call, and the stock slipped 0.9% that day. Craig-Hallum's October 2 target increase to USD 8 from USD 4 came as shares moved toward USD 4.575, which they reached on October 5. By October 8 the stock had given back about 10% from that level to USD 4.13, per the screener. The stock closed at USD 3.36 on September 10 and USD 3.79 on September 14 before the commercial change.

Risks and What to Watch

The 52-week range is USD 2.74 to USD 8.59, so the stock remains far below its high, and profitability is the central worry. Analysts disagree sharply, with targets running from USD 2 to USD 8, which shows how uncertain the turnaround is. A commercial Leadership change in the middle of a push can disrupt sales execution. No catalyst for the mid-September jump was found, so some of it may be short covering or relief buying. Watch the third quarter report, estimated for November 2, 2026, for guidance and Margin progress. The July 30 guidance remains the latest financial update from the company, so the debate rests on whether profitability improves. Genetic testing reimbursement and competition could also weigh on margins.

Where Things Stand

Myriad Genetics (NASDAQ:MYGN) rose about 30% in a month mainly as a rebound from a September low after sharp analyst downgrades, helped by Craig-Hallum's raised target. No company release explains the mid-September jump, and a sales leadership change adds uncertainty. Profitability and the November 2 estimated report are the key tests. The stock gave back about 10% from its October 5 close, which shows the move is not settled. Myriad Genetics (NASDAQ:MYGN) has to prove the downgrades were too harsh.